NRF2-targeted therapeutics: New targets and modes of NRF2 regulation.

Pharmacological activation of the transcription factor nuclear factor-erythroid derived 2-like 2 (NRF2), the key regulator of the cellular antioxidant response, has been recognized as a feasible strategy to reduce oxidative/electrophilic stress and prevent carcinogenesis or other chronic illnesses, such as diabetes and chronic kidney disease. In contrast, due to the discovery of the "dark side" of NRF2, where prolonged activation of NRF2 causes tissue damage, cancer progression, or chemoresistance, efforts have been devoted to identify inhibitors. Currently, only one NRF2 activator has been approved for use in the clinic, while no specific NRF2 inhibitors have been discovered. Future development of NRF2-targeted therapeutics should be based on our current understanding of the regulatory mechanisms of this protein. In addition to the KEAP1-dependent mechanisms, the recent discovery of other pathways involved in the degradation of NRF2 have opened up new possibilities for the development of safe and specific therapeutics. Here, we review available and putative NRF2-targeted therapeutics and discuss their modes of action as well as their potential for disease prevention and treatment.

[1]  L. Cai,et al.  The role of the Nrf2/Keap1 pathway in obesity and metabolic syndrome , 2015, Reviews in Endocrine and Metabolic Disorders.

[2]  James Lee,et al.  Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis , 2015, Molecular & Cellular Proteomics.

[3]  G. Baillie,et al.  PKA phosphorylation of p62/SQSTM1 regulates PB1 domain interaction partner binding. , 2014, Biochimica et biophysica acta.

[4]  K. Itoh,et al.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. , 1997, Biochemical and biophysical research communications.

[5]  Donna D. Zhang,et al.  Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism , 2011, Proceedings of the National Academy of Sciences.

[6]  W. Zong,et al.  TRIM21 Ubiquitylates SQSTM1/p62 and Suppresses Protein Sequestration to Regulate Redox Homeostasis. , 2016, Molecular cell.

[7]  T. Nakajima,et al.  Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis , 2014, Genes & development.

[8]  A. Cuadrado,et al.  Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. , 2012, Oncogene.

[9]  T. Mizushima,et al.  Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. , 2013, Molecular cell.

[10]  Q. You,et al.  Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis. , 2014, Journal of medicinal chemistry.

[11]  Mihee M. Kim,et al.  The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1 , 2010, Nature Cell Biology.

[12]  G. Wells.  Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction. , 2015, Biochemical Society transactions.

[13]  L. Wattenberg.  Inhibitors of chemical carcinogenesis. , 1978, Advances in cancer research.

[14]  J. Garcia,et al.  Bixin protects mice against ventilation-induced lung injury in an NRF2-dependent manner , 2016, Scientific Reports.

[15]  Myungjin Kim,et al.  Sestrin2 promotes Unc‐51‐like kinase 1 mediated phosphorylation of p62/sequestosome‐1 , 2014, The FEBS journal.

[16]  Joachim Kraemer,et al.  Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. , 2013, Bioorganic & medicinal chemistry.

[17]  Steven B. Bradfute,et al.  TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. , 2012, Immunity.

[18]  B. Levine,et al.  Autosis and autophagic cell death: the dark side of autophagy , 2014, Cell Death and Differentiation.

[19]  A. Kong,et al.  Optimization of Fluorescently Labeled Nrf2 Peptide Probes and the Development of a Fluorescence Polarization Assay for the Discovery of Inhibitors of Keap1-Nrf2 Interaction , 2012, Journal of biomolecular screening.

[20]  T. Kensler,et al.  Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane. , 2016, Seminars in oncology.

[21]  Donna D. Zhang,et al.  The emerging role of the Nrf2–Keap1 signaling pathway in cancer , 2013, Genes & development.

[22]  S. Sehgal.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. , 1998, Clinical biochemistry.

[23]  A. Kong,et al.  Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis , 2010, Cancer and Metastasis Reviews.

[24]  M. McMahon,et al.  p62/SQSTM1 Is a Target Gene for Transcription Factor NRF2 and Creates a Positive Feedback Loop by Inducing Antioxidant Response Element-driven Gene Transcription* , 2010, The Journal of Biological Chemistry.

[25]  She Chen,et al.  Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy , 2010, Autophagy.

[26]  K. Ward,et al.  Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers , 2015, BMC Dermatology.

[27]  W. Zong.  Corrections to "TRIM21 Ubiquitylates SQSTM1/p62 and Suppresses Protein Sequestration to Regulate Redox Homeostasis "[Molecular Cell 61, 720-733; March 3, 2016] , 2016 .

[28]  Donna D. Zhang,et al.  The Cinnamon-Derived Dietary Factor Cinnamic Aldehyde Activates the Nrf2-Dependent Antioxidant Response in Human Epithelial Colon Cells , 2010, Molecules.

[29]  I. Benjamin,et al.  Reductive stress linked to small HSPs, G6PD, and Nrf2 pathways in heart disease. , 2013, Antioxidants & redox signaling.

[30]  Hye Eun Lee,et al.  Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. , 2013, Cell metabolism.

[31]  J. Hayes,et al.  Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction. , 2012, Free radical biology & medicine.

[32]  Nadine H. Elowe,et al.  An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase , 2010, Nature Biotechnology.

[33]  P. Wong,et al.  Dual roles of Nrf2 in cancer. , 2008, Pharmacological research.

[34]  Ken Itoh,et al.  Redox-regulated Turnover of Nrf2 Is Determined by at Least Two Separate Protein Domains, the Redox-sensitive Neh2 Degron and the Redox-insensitive Neh6 Degron* , 2004, Journal of Biological Chemistry.

[35]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[36]  Mark Hannink,et al.  Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex , 2004, Molecular and Cellular Biology.

[37]  P. Rada,et al.  Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3. , 2012, Free radical biology & medicine.

[38]  Bob van de Water,et al.  The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  Donna D. Zhang.  Bardoxolone brings Nrf2-based therapies to light. , 2013, Antioxidants & redox signaling.

[40]  Q. You,et al.  Novel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening , 2014 .

[41]  E. White,et al.  A Noncanonical Mechanism of Nrf2 Activation by Autophagy Deficiency: Direct Interaction between Keap1 and p62 , 2010, Molecular and Cellular Biology.

[42]  C. Wolf,et al.  Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha , 2007, Proceedings of the National Academy of Sciences.

[43]  Y. Li,et al.  Chemical genetics of TOR identifies an SCF family E3 ubiquitin ligase inhibitor , 2010, Nature Biotechnology.

[44]  J. D. Engel,et al.  Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. , 1999, Genes & development.

[45]  S. Lipton,et al.  Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. , 2013, Free radical biology & medicine.

[46]  T. Hoffmann,et al.  Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.

[47]  J. Callahan,et al.  Keap calm, and carry on covalently. , 2013, Journal of medicinal chemistry.

[48]  P. Rada,et al.  SCF/β-TrCP Promotes Glycogen Synthase Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner , 2011, Molecular and Cellular Biology.

[49]  P. Talalay,et al.  Elevation of hepatic glutathione S-transferase activities and protection against mutagenic metabolites of benzo(a)pyrene by dietary antioxidants. , 1978, Cancer research.

[50]  S. Schreiber,et al.  Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. , 2013, Bioorganic & medicinal chemistry letters.

[51]  A. Limonciel,et al.  A Review of the Evidence that Ochratoxin A Is an Nrf2 Inhibitor: Implications for Nephrotoxicity and Renal Carcinogenicity , 2014, Toxins.

[52]  N. Nukina,et al.  Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins. , 2011, Molecular cell.